×

MorphoSys AG: Corporate Calendar 2015

MARTINSRIED / MUNICH, Germany, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Dear Madam/Sir,

Please note MorphoSys's financial reporting dates 2015 as follows:

26 February 2015: Year-end 2014 Results
5 May 2015: Publication of Three Months' Report 2015
27 July 2015: Publication of Six Months' Report 2015
4 November 2015: Publication of Nine Months' Report 2015

8 May 2015: Annual General Meeting in Munich

For a direct import of the dates to your calendar, please visit our corporate website: http://www.morphosys.com/media-investors/events/company-calendar

With season's greetings and good wishes for the New Year:
http://www.morphosys.com/xmas-2014

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Specialist Corporate Communications & IR

Jessica Rush
Specialist Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media Release (PDF) http://hugin.info/130295/R/1882713/664282.pdf

HUG#1882713

Source:MorphoSys AG